Bose Arani, an insider at Penumbra Inc (PEN), sold 275,261 shares on November 24, 2025, at a price of $300.19 per share. The total transaction value reached $82.63 million. Following this sale, Arani retains 275,261 shares in the company.
Penumbra, headquartered in Alameda, California, specializes in innovative medical products, particularly in thrombectomy. The company targets conditions like Pulmonary Embolism and Deep Vein Thrombosis, aiming to improve clinical outcomes through its advanced technologies. With a market capitalization of $11.6 billion and a P/E ratio of 70.66, Penumbra is positioned as a key player in the healthcare industry.
Insider transactions are reported to the SEC, providing transparency into executive stock movements. While such sales can reflect personal financial decisions, they do not inherently indicate negative sentiment toward the company. Investors are advised to consider broader patterns of insider activity rather than isolated transactions when assessing these signals.
Penumbra is expected to announce its next earnings on July 27, 2026, with an estimated EPS of $1.21 and revenue of $391.3 million.